

2020-2021 clinical priorities and expected milestones

EDP1815 <i>COVID-19</i>	<ul style="list-style-type: none">Data from Phase 2 trial	2H 2020
EDP1815 <i>Psoriasis</i>	<ul style="list-style-type: none">Initiate Phase 2 trialInterim data from Phase 2 trial	3Q 2020 Mid-2021
EDP1867 <i>Atopic Diseases</i>	<ul style="list-style-type: none">Initiate Phase 1b trial	1Q 2021
EDP1503 <i>Triple-negative Breast Cancer</i>	<ul style="list-style-type: none">Updated clinical data from Phase 1/2 trial	2H 2020

Continue to explore platform breadth, advancing preclinical programs and exploring additional indications for clinical compounds